NCT05376891 Met Non Small Cell Cancer Registry (MOMENT)
| NCT ID | NCT05376891 |
| Status | Recruiting |
| Phase | — |
| Sponsor | EMD Serono Research & Development Institute, Inc. |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 700 participants |
| Start Date | 2022-10-04 |
| Primary Completion | 2028-04-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 700 participants in total. It began in 2022-10-04 with a primary completion date of 2028-04-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this multi-national disease registry is to collect prospectively (with longitudinal follow-up) high-quality, standardized, and contemporaneous data to capture changes in the non-small cell lung cancer (NSCLC) treatment landscape and outcomes over time. The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14(METex14) participants treated with systemic therapy.
Eligibility Criteria
Inclusion Criteria: * Participants who signed ICF * Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay) * Participants who are starting or are already being treated with systemic therapy Exclusion Criteria: * Participants who are enrolled in a clinical trial
Contact & Investigator
Medical Responsible
STUDY DIRECTOR
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Frequently Asked Questions
Who can join the NCT05376891 clinical trial?
This trial is open to participants of all sexes, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05376891 currently recruiting?
Yes, NCT05376891 is actively recruiting participants. Contact the research team at eMediUSA@emdserono.com for enrollment information.
Where is the NCT05376891 trial being conducted?
This trial is being conducted at Fort Lauderdale, United States, Columbus, United States, Nashville, United States, Klagenfurt, Austria and 11 additional locations.
Who is sponsoring the NCT05376891 clinical trial?
NCT05376891 is sponsored by EMD Serono Research & Development Institute, Inc.. The principal investigator is Medical Responsible at Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. The trial plans to enroll 700 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.